美国Pathwork Diagnostics  
Pathwork Diagnostics公司是一家从事肿瘤疾病分子诊断技术研发的企业，该公司宣布在一轮融资中获得来自Abingworth总额为2000万美元的投资。据悉，在募资消息宣布前不久，Pathwork Diagnostics公司已经得到了食品和药物管理局（FDA）关于对一些不确定病原型肿瘤进行组织病原测试的许可，这些不确定病原肿瘤包括那些低分化，未分化和转移性肿瘤。

Pathwork Diagnostics, Inc., is a privately held company in Redwood City, CA, that develops and commercializes innovative, high-value molecular diagnostics for oncology. The company’s Pathwork® Tissue of Origin Test is a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. It is the only FDA-cleared and Medicare-covered molecular test of its kind. The company provides the Tissue of Origin Test through its CLIA-certified, CAP-accredited laboratory.
In the U.S., approximately 150,000 newly diagnosed cancer patients may have a tumor that is metastatic, undifferentiated, or poorly differentiated, and often difficult to diagnose. These patients may benefit from the Tissue of Origin Test, because knowing the site of origin for these challenging tumors may lead to more effective treatment.